1.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 to 74 Sponsor: NCI, Other Protocol IDs: MA32, U10CA077202, CAN-NCIC-MA.32, CDR0000669788, NCIC-MA.32, NCT01101438
|
|
2.
|
Phase: Phase II Type: Treatment Status: Closed Age: 21 and over Sponsor: Other Protocol IDs: AAAD6525, NCT00930579
|
|
3.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SAKK 08/09, SWS-SAKK-08/09, CDR0000688789, EU-21084, NCT01243385
|
|
4.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-03451, MAY10-15-03, MAYO-MAY10-15-03, CDR0000698069, NCT01447927
|
|
5.
|
Phase: Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-LRCC-UWOREB13877, UWOREB13877, WYETH-CAN-LRCC-UWOREB13877, NCT00659568
|
|
6.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 2008-0284, NCT00933309
|
|
7.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 70 Sponsor: Other Protocol IDs: METFORMIN, NCT00897884
|
|
8.
|
Phase: No phase specified Type: Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: 10-244, NCT01215032
|
|
9.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Tissue collection/Repository Status: Closed Age: 18 to 74 Sponsor: NCI, Other Protocol IDs: NSABP MA.32.F, NSABP-NCIC-CTG-MA.32.F, NCT01286233
|